» Articles » PMID: 25230372

MiR-506 Inhibits Multiple Targets in the Epithelial-to-mesenchymal Transition Network and is Associated with Good Prognosis in Epithelial Ovarian Cancer

Overview
Journal J Pathol
Specialty Pathology
Date 2014 Sep 18
PMID 25230372
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Extensive investigations have shown that miRNAs are important regulators of epithelial-to-mesenchymal transition (EMT), mainly targeting the transcriptional repressors of E-cadherin (E-cad). Less is known about the post-transcriptional regulation of vimentin or N-cadherin (N-cad) in EMT. Our previous study identified miR-506 as a key EMT inhibitor through directly targeting the E-cad transcriptional repressor SNAI2. In this study, we provide evidence that miR-506 simultaneously suppresses vimentin and N-cad. The knockdown of vimentin using siRNA reversed EMT, suppressed cell migration and invasion, and increased E-cad expression on the cell membrane in epithelial ovarian cancer (EOC) cells. In a set of tissue microarrays that included 204 EOCs of all major subtypes (eg serous, endometrioid, clear cell, and mucinous), miR-506 was positively correlated with E-cad and negatively correlated with vimentin and N-cad in all subtypes of EOC. A high level of miR-506 was positively associated with early FIGO stage and longer survival in EOC. Introduction of miR-506, mediated by nanoparticle delivery, in EOC orthotopic mouse models resulted in decreased vimentin, N-cad, and SNAI2 expression and increased E-cad expression; it also suppressed the dissemination of EOC cells. Thus, miR-506 represents a new class of miRNA that regulates both E-cad and vimentin/N-cad in the suppression of EMT and metastasis.

Citing Articles

Exploring public cancer gene expression signatures across bulk, single-cell and spatial transcriptomics data with signifinder Bioconductor package.

Pirrotta S, Masatti L, Bortolato A, Corra A, Pedrini F, Aere M NAR Genom Bioinform. 2024; 6(4):lqae138.

PMID: 39363890 PMC: 11447528. DOI: 10.1093/nargab/lqae138.


Prognostic significance of non-coding RNAs related to the tumorigenic epithelial-mesenchymal transition (EMT) process among ovarian cancer patients: A systematic review and meta-analysis.

Khaboushan A, Salimian S, Mehraban S, Bahramy A, Zafari N, Kajbafzadeh A Heliyon. 2024; 10(16):e35202.

PMID: 39253159 PMC: 11382180. DOI: 10.1016/j.heliyon.2024.e35202.


Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance.

Tabatabaee A, Nafari B, Farhang A, Hariri A, Khosravi A, Zarrabi A Cancer Metastasis Rev. 2023; 43(1):363-377.

PMID: 38012357 DOI: 10.1007/s10555-023-10154-7.


The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis.

Zheng C, Li R, Zheng S, Fang H, Xu M, Zhong L Cancer Sci. 2023; 114(12):4747-4762.

PMID: 37817462 PMC: 10728003. DOI: 10.1111/cas.15989.


Palbociclib suppresses the cancer stem cell properties and cell proliferation through increased levels of miR-506 or miR-150 in Panc-1 and MiaPaCa-2 cells.

Rencuzogullari O, Arisan E Turk J Biol. 2023; 46(5):342-360.

PMID: 37529006 PMC: 10387936. DOI: 10.55730/1300-0152.2622.


References
1.
Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

2.
Peter M . Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle. 2009; 8(6):843-52. PMC: 2688687. DOI: 10.4161/cc.8.6.7907. View

3.
Cheng C, Wang H, Chang C, Chu H, Chen C, Yu J . MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res Treat. 2012; 134(3):1081-93. DOI: 10.1007/s10549-012-2034-4. View

4.
Gelmon K, Tischkowitz M, MacKay H, Swenerton K, Robidoux A, Tonkin K . Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011; 12(9):852-61. DOI: 10.1016/S1470-2045(11)70214-5. View

5.
Min C, Eddy S, Sherr D, Sonenshein G . NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem. 2008; 104(3):733-44. DOI: 10.1002/jcb.21695. View